NAA15: The Geneticsand the Science
Understanding the molecular biology of NAA15, how variants cause disease, and why genetic testing — including Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), or Targeted Gene Panels — is required to confirm a diagnosis.
The Genetics of NAA15
The NAA15 gene encodes the auxiliary subunit of the NatA Complex. NatA is one of the most abundant protein complexes in human cells, responsible for the co-translational acetylation of the N-terminus of approximately 40% of all human proteins. This chemical modification — called N-Terminal Acetylation — affects protein stability, folding, localization, and function across virtually every cellular process.
NAA15 works in partnership with NAA10, the catalytic subunit of NatA. NAA15 acts as the Ribosome-anchoring subunit, positioning the complex to acetylate newly synthesized proteins as they emerge from the ribosome. When NAA15 is disrupted by a Pathogenic Variant, the entire NatA complex is destabilized. NAA10 loses its ribosomal anchor, and the acetylation of hundreds of downstream proteins is impaired — a consequence of Haploinsufficiency.
The downstream effects are particularly severe during brain development, when precise protein regulation is essential for neuronal migration, synaptic formation, and cortical organization. This explains why NAA15 variants produce a neurodevelopmental Phenotype, and why the effects are so broad and variable across individuals — a phenomenon known as Variable Expressivity.
Read: NatA Complex Mechanism (PMC)Gene Location
Chromosome 4q22.1
Gene Function
Auxiliary subunit of NatA N-terminal acetyltransferase complex
Protein Role
Ribosome anchoring; enables co-translational N-terminal acetylation
Proteins Affected
~40% of all human proteins require NatA acetylation
Inheritance
Autosomal dominant; most often de novo, inherited cases also reported
Recurrence Risk
~1% (gonadal mosaicism); parents typically unaffected
Variant Types
Loss-of-function, missense, frameshift, splice-site
First Described
2018, Cheng et al., AJHG
Genetic Testing is Required to Confirm NAA15
Standard clinical tests cannot identify NAA15. Brain MRI, EEG (Electroencephalogram), chromosomal microarray, and metabolic panels may all return normal results in an individual with NAA15. Confirmation requires genetic sequencing — through Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), or a Targeted Gene Panel — to identify the specific Pathogenic Variant.
Whole Exome Sequencing (WES)
Sequences all ~20,000 protein-coding genes. The most common route to NAA15 diagnosis. Identifies loss-of-function, missense, frameshift, and splice-site variants in NAA15.
Trio-WES (Gold Standard)
Tests the child and both biological parents simultaneously. Confirms the de novo nature of the NAA15 variant, rules out inherited causes, and provides the most definitive diagnostic result. Strongly recommended.
Genome Sequencing
Broader than exome sequencing, covering non-coding regions as well. May identify NAA15 variants missed by exome sequencing, particularly intronic or regulatory variants.
Tests That Cannot Diagnose NAA15
NAA15 Research Timeline
From first description to international registry, the science of NAA15 has moved quickly. Each milestone represents families who shared their stories and researchers who listened.
NAA15 First Described — International Cohort
Cheng et al. published the landmark paper in AJHG identifying de novo and inherited variants in NAA15 in 38 individuals from 33 unrelated families across institutions in the US, Netherlands, UK, Australia, Belgium, France, Italy, Canada, and Norway. This global collaboration established NAA15 as a distinct neurodevelopmental syndrome.
Cheng et al., AJHG 2018NatA Complex Mechanism Elucidated
Concurrent structural and functional studies detailed how NAA15 variants destabilize the NatA N-terminal acetyltransferase complex, disrupting co-translational acetylation of approximately 40% of all human proteins. Yeast functional assays confirmed loss-of-function for multiple variants. Norwegian biochemists (Arnesen lab, University of Bergen) contributed key mechanistic data.
PMC: NatA Complex StudyInternational Phenotypic & Biochemical Analysis
Cheng et al. published a follow-up international cohort study with phenotypic and biochemical analysis of individuals with variants in NAA10 and NAA15. Expanded the clinical picture and confirmed variable expressivity — including that severity can differ even between individuals with the same variant within the same family.
PMC6736318: International Cohort 2019Cardiac Mechanism Paper — AHA Journals
Ward et al. published in Circulation Research detailing the mechanisms of congenital heart disease caused by NAA15 haploinsufficiency. This cardiac-focused study from the American Heart Association journals established the molecular basis for cardiac involvement and prompted routine cardiology evaluation at diagnosis.
AHA Journals: NAA15 & CHD MechanismPediatric Cardiomyopathy Documented
Ritter et al. published the first dedicated study linking NAA15 pathogenic variants to pediatric hypertrophic cardiomyopathy, expanding the known cardiac phenotype beyond structural defects to include cardiomyopathy.
PMC8007079: NAA15 & CardiomyopathyChinese Developmental Cohort — Catch-Up Trajectories
Tian et al. (Capital Institute of Pediatrics, Beijing) screened 769 Chinese NDD children and identified 4 NAA15 variants (0.52% frequency), including one maternal (inherited) case. Crucially, they documented possible catch-up developmental trajectories in 3 of 4 patients — an important finding for prognosis and counseling.
PMC8954815: Chinese Cohort 2022Expanding Phenotypic Spectrum — Lyon et al.
Lyon et al. published in European Journal of Human Genetics (Nature) expanding the known phenotypic spectrum of NAA10 and NAA15-related neurodevelopmental syndrome. Documented variable expressivity, both de novo and inherited inheritance patterns, and broader clinical features across a larger international cohort.
Nature/EJHG: Lyon et al. 2023ERN ITHACA: Adult Phenotype Initiative (Europe)
The European Reference Network for Rare Congenital Malformations (ERN ITHACA) launched a call for collaboration specifically on NAA15-associated disorder beyond childhood — recognizing a critical gap in understanding the adult phenotype and long-term outcomes.
ERN ITHACA: NAA15 Beyond ChildhoodNeuroimaging Study — Brain Anatomy in NAA15
Patel, Makwana et al. published the first dedicated neuroimaging analysis of NAA10 and NAA15 patients. NAA15 individuals had an average of 2.8 anatomical abnormalities (vs 5.7 for NAA10). Brain MRI is often reported as 'normal' in routine care, but expert neuroradiological review reveals subtle findings including pons volume changes and occasional white matter lesions.
PMC11230317: Neuroimaging Study 2024Natural History Through Adolescence
Makwana et al. published a natural history study of NAA15-related neurodevelopmental disorder through adolescence, providing the most comprehensive longitudinal clinical picture to date. Simons Searchlight registry data continues to grow, enabling systematic tracking of developmental trajectories.
PubMed 38978667: Natural History 2024Clinical Case Illustrations
These illustrative cases are drawn from published literature and represent the range of presentations seen in NAA15. They are intended to help families and clinicians recognize the diagnostic patterns.
Case 1: International Cohort — Inherited Variant (Family 10)
Multiple affected family membersPresentation
Proband at age 17.5 years: prominent eyebrows, broad nose, prominent chin. Sibling at 6.5 years: well-developed philtral pillars. Mother: long mentum, relatively thick alae nasi — mildly affected.
Genetic Finding
Familial NAA15 LGD variant (c.239_240delAT) segregating across three family members. Mother was only mildly affected, demonstrating variable expressivity within the same family. Confirmed via trio-WES at Baylor College of Medicine.
Outcome
Demonstrates that inherited NAA15 cases exist and that expressivity varies even within families. The mildly affected parent had not previously received a diagnosis. Enrolled in international registry.
Cheng et al. (2018), AJHG — Family 10, international cohort
Case 2: Chinese Cohort — Catch-Up Developmental Trajectory
Patient 1: 13 months at first assessment, 37 months at follow-upPresentation
Global developmental delay at 13 months (DQ scores 60–67 across all subscales). Mild broad nasal bridge, large forehead. Hypertonia after birth. Failed to keep head upright at 5 months.
Genetic Finding
De novo missense variant in NAA15 (c.1321G>A, p.D441N) identified by WES at Capital Institute of Pediatrics, Beijing. Brain MRI and cardiac ultrasound normal.
Outcome
At 37 months follow-up, DQ improved significantly (gross motor 104, language 85). Walked at 16 months, jumped at 29 months, expressed meaningful words at 30 months after physical rehabilitation. Demonstrates possible catch-up trajectory with early intervention.
Tian et al. (2022), Genes — Chinese NDD cohort, PMC8954815
Case 3: Cardiac Presentation — Hypertrophic Cardiomyopathy
Age 2 at genetic diagnosisPresentation
Hypertrophic cardiomyopathy identified at 8 months, developmental delay, hypotonia. Genetic workup initiated by cardiology team. No obvious dysmorphic features noted.
Genetic Finding
Exome sequencing identified a de novo frameshift variant in NAA15. Cardiac involvement prompted immediate cardiology co-management. Consistent with Ritter et al. (2021) documenting NAA15 variants in pediatric HCM.
Outcome
Ongoing cardiac monitoring with echocardiography. Developmental therapies initiated. Family enrolled in Simons Searchlight registry. Illustrates the importance of cardiac evaluation at NAA15 diagnosis.
Based on Ritter et al. (2021), AJMG — PMC8007079; cardiac phenotype reports
Case 4: Neuroimaging — Subtle Brain Findings
Age 1–15 years (NAA15 neuroimaging cohort)Presentation
8 NAA15 probands underwent dedicated neuroradiological review. Brain MRI had been reported as 'normal' in routine clinical care for most.
Genetic Finding
Expert neuroradiological review (Patel et al., 2024) found an average of 2.8 anatomical abnormalities per NAA15 proband. Findings included pons volume changes (3/8), occasional white matter lesions, and mild 4th ventricle enlargement. No globus pallidus hyperintensity (unlike NAA10).
Outcome
Highlights that routine clinical MRI reporting may underestimate subtle neuroanatomical findings in NAA15. Expert neuroradiology review is valuable. NAA15 neuroimaging is generally less severe than NAA10 (Ogden syndrome).
Patel, Makwana et al. (2024), medRxiv/PMC11230317 — neuroimaging study
Life Expectancy & Long-Term Outlook
NAA15 is not described as a life-limiting condition in the published literature. The oldest documented individuals in published cohorts are adults, and no pattern of premature mortality has been established. However, several medical variables — particularly Congenital Heart Disease (CHD) and Seizures — can meaningfully affect health outcomes and require active, lifelong monitoring.
General Outlook
Based on published cohort data, individuals with NAA15 are expected to have a near-normal lifespan when cardiac and neurological complications are identified and managed early. The condition primarily affects quality of life and developmental trajectory rather than longevity.
Note: NAA15 was only described in 2018. Long-term adult outcome data is limited. ERN ITHACA launched a dedicated adult phenotype initiative in 2023 to address this gap.
Key Variables That Affect Health Outcomes
Cardiac Anomalies (~21% of individuals)
Moderate–HighCongenital heart defects and hypertrophic cardiomyopathy (HCM) are the most significant life-affecting variables in NAA15. Undetected or unmanaged cardiac disease — particularly HCM — carries risk of arrhythmia and sudden cardiac events. Routine echocardiography at diagnosis and regular cardiology follow-up are strongly recommended. When identified and managed, most cardiac conditions in NAA15 are treatable.
Ward et al., Circulation Research 2021; Ritter et al., PMC8007079
Seizures / Epilepsy (~23–31% of individuals)
ModerateSeizures occur in approximately one in four individuals with NAA15. Most seizure types seen in NAA15 (absence, focal, tonic-clonic) are manageable with anti-seizure medications. Poorly controlled epilepsy carries risks including SUDEP (sudden unexpected death in epilepsy), though this has not been specifically documented in NAA15 cohorts. EEG monitoring and neurological follow-up are standard care.
Cheng et al., AJHG 2018; Makwana et al., AJMG 2024
Aspiration Risk from Feeding Difficulties (~57% of individuals)
Low–ModerateFeeding difficulties and oral motor dysfunction in infancy and early childhood can lead to aspiration pneumonia if not managed. Feeding therapy, appropriate food textures, and in some cases gastrostomy tube placement reduce this risk significantly. Most feeding difficulties improve with age and intervention.
Cheng et al., AJHG 2018; Simons Searchlight Gene Guide
Intellectual Disability & Adaptive Functioning (~100% of individuals)
LifelongIntellectual disability does not directly shorten lifespan, but it affects independence and the ability to self-manage health. Individuals with more severe cognitive impairment require lifelong support and are more dependent on caregivers for health monitoring. Adults with intellectual disability as a group have higher rates of undetected health conditions — underscoring the importance of ongoing specialist care into adulthood.
ERN ITHACA Adult Phenotype Initiative, 2023
Vision & Neurological Complications
VariableCortical visual impairment (CVI), strabismus, and subtle brain anatomical findings (avg. 2.8 abnormalities on expert MRI review) are documented in NAA15. These do not typically affect lifespan but can affect quality of life and safety. Regular ophthalmology and neurology follow-up are recommended.
Patel et al., PMC11230317 & PMC10862986, 2024
Important Note on Data Limitations
NAA15 was first described in 2018. Published cohorts are small and skewed toward children and adolescents. No large-scale adult mortality data exists for NAA15 specifically. The statements above are based on the best available evidence from published case series and registry data, and on what is known about comparable neurodevelopmental conditions. Families should discuss prognosis directly with their specialist team. This content does not constitute medical advice.
References
All scientific content on this page is drawn from peer-reviewed literature and trusted rare disease databases.
Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice. Consult a qualified clinical geneticist or specialist for guidance specific to your situation.
Ready to explore the research?
See the published studies, research timeline, and how you can contribute to advancing NAA15 science.